In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.

The Journal of Antimicrobial Chemotherapy
Xiaojuan WangHui Wang

Abstract

To evaluate in vitro activity of the novel β-lactamase boronate inhibitor taniborbactam (VNRX-5133) combined with cefepime or meropenem against 500 urinary Gram-negative bacilli. Cefepime/taniborbactam and 14 comparators were tested by broth microdilution or agar dilution methods. A total of 450 Enterobacteriaceae and 50 Pseudomonas aeruginosa were selected from 2017 to 2019 based on different β-lactamase-producing or resistance phenotypes. For carbapenem-non-susceptible isolates, the modified carbapenem inactivation method (mCIM), EDTA-CIM (eCIM) and amplification of carbapenemase genes were performed. For NDM-producing isolates and those with cefepime/taniborbactam MICs >8 mg/L, the MICs of meropenem/taniborbactam and/or mutations in PBP3 were investigated. Taniborbactam improved cefepime activity with the same efficiency as avibactam improved ceftazidime activity against 66 KPC-2 producers, 30 non-carbapenemase-producing carbapenem-non-susceptible Enterobacteriaceae and 28 meropenem-susceptible P. aeruginosa. However, cefepime/taniborbactam exhibited more potent activity than ceftazidime/avibactam against 56 ESBL-producing, 61 AmpC-producing, 32 ESBL and AmpC co-producing, 87 NDM-producing and 21 MBL-producing Enterobacteria...Continue Reading

References

Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Mar 15, 2011·Diagnostic Microbiology and Infectious Disease·Laurent PoirelPatrice Nordmann
Mar 15, 2011·The Journal of Antimicrobial Chemotherapy·Yan ChenYunsong Yu
Jun 23, 2016·Cold Spring Harbor Perspectives in Medicine·Karen Bush, Patricia A Bradford
Sep 15, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ryan K ShieldsM Hong Nguyen
Oct 8, 2016·Postgraduate Medicine·Mazen S BaderAnnie A Brooks
Mar 10, 2017·Virulence·Enrico Maria Trecarichi, Mario Tumbarello
Oct 24, 2018·The Journal of Antimicrobial Chemotherapy·David M Livermore
Nov 14, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Qi WangHui Wang
Nov 27, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara TomczykStephan Harbarth
Feb 1, 2019·Clinical Microbiology Reviews·Wenjing WuZhiyong Zong
Feb 15, 2019·Frontiers in Microbiology·Chau-Chyun SheuPo-Ren Hsueh
Mar 7, 2019·Nature Reviews. Microbiology·Karen Bush, Patricia A Bradford
Apr 9, 2019·Journal of Molecular Biology·Catherine L TookeJames Spencer
May 16, 2019·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Kati RäisänenJari Jalava
Aug 28, 2019·Journal of Medicinal Chemistry·Alen KrajncChristopher J Schofield

❮ Previous
Next ❯

Citations

Mar 28, 2020·International Journal of Environmental Research and Public Health·Yanling WangJianfeng Wang
Oct 4, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Rajeev SomanBalaji Veeraraghavan
Nov 4, 2020·Future Microbiology·Matteo BassettiDaniele R Giacobbe
Dec 4, 2020·Infection and Drug Resistance·Toni A Campanella, Jason C Gallagher
Dec 10, 2020·International Journal of Molecular Sciences·Juan C Vázquez-UchaAlejandro Beceiro
Jan 28, 2021·Infection and Drug Resistance·Xing TanZackery P Bulman
Dec 12, 2020·The Journal of Antimicrobial Chemotherapy·Shazad MushtaqDavid M Livermore
Nov 18, 2020·International Journal of Molecular Sciences·Corneliu Ovidiu VrancianuMariana Carmen Chifiriuc

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.